advances in the risk stratification and treatment of essential thrombocythemia
Published 1 year ago • 2.7K plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
3:21
the current standard of care for patients with essential thrombocythemia
-
1:43
updates from a phase ii study of bomedemstat for the treatment of essential thrombocythemia
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
8:14
chronic blood cancer at 30 | essential thrombocytosis | mpn
-
3:53
essential thrombocythemia watch & wait | what patients should know
-
6:40
doctor explains high platelet count (thrombocytosis) | causes, symptoms and more
-
2:09
advances in the management of fit adults with aml
-
2:41
an overview of the latest advances in hematology
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:34
are thrombotic risk and progression in et predictable?
-
3:40
final analysis of the phase 4 exels trial in high-risk patients with essential thrombocythemia
-
8:07
essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies
-
1:57
surpass et: p1101 in essential thrombocythemia
-
2:02
recent advances in all treatment
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024
-
4:02
mpns and thrombosis: reducing the risk
-
2:00
the role of fedratinib in 2024 and beyond
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
0:47
novel agents being explored for the treatment of immune-mediated ttp